BBP ETF Explained: Returns, Expense Ratio, Holdings, and Alternative ETFs
The Virtus LifeSci Biotech Products ETF (BBP) concentrates on biotech companies that hold FDA-approved drugs. It can be a useful choice for investors who want exposure to commercial-stage companies with lower risk than early clinical-stage names, and who also want to compare related funds and check dividend characteristics.
SubscribeWhat Is the Virtus LifeSci Biotech Products ETF?
The fund tracks the LifeSci Biotech Products Index, which is made up of biotech companies that hold FDA-approved drugs. It offers concentrated exposure to commercial-stage companies that have already proven clinical success.
It suits investors who want exposure to the biotech sector but want to reduce the risk of early-stage clinical failures.
This is a passively managed (index-tracking) ETF run by Virtus.
How Does the Virtus LifeSci Biotech Products ETF Invest?
| Item | Details |
|---|---|
| Tracked Index | LifeSci Biotech Products Index |
| Management Style | Passive (index tracking) |
| Rebalancing Frequency | Quarterly |
| Dividend Frequency | Growth-oriented portfolio that focuses on capital gains rather than dividends |
| Expense Ratio | 0.34% |
Only biotech companies with at least one FDA-approved drug are eligible for inclusion, which screens out early-stage companies with high clinical failure risk. The index constituents are reviewed regularly to make sure they continue to meet the eligibility requirements.
- A filtering strategy that selects only commercial-stage companies
- A near equal-weighted approach to diversification that reduces concentration in individual stocks
Virtus LifeSci Biotech Products ETF Size and Costs (AUM and Management Fee)
Assets under management (AUM) stand at $137.5M, and the expense ratio is 0.34% per year.
Compared with the broad healthcare ETFs shown in the table, such as XLV and VHT, this fund is concentrated in a single sector, biotech, so its volatility tends to be higher.
Virtus LifeSci Biotech Products ETF Performance and Trends
1-Year Price Performance
Dividend & Yield
52-Week Price RangeGiven the nature of the biotech sector, the fund has shown sharp short-term volatility driven by clinical and regulatory news on individual stocks. Interest rate conditions and new drug approval news influence the direction of the sector as a whole.
Fund flows tend to be volatile as investor sentiment toward biotech shifts, and interest tends to build when healthcare policy issues or M&A expectations come into focus.
Virtus LifeSci Biotech Products ETF Strengths and Weaknesses
Its focus on commercial-stage companies with lower clinical failure risk is a strength, while the high volatility that comes with sector concentration deserves attention.
💪 Key Strengths
⚠️ Risks to Consider
Virtus LifeSci Biotech Products ETF Alternatives and Related Products
XLV, VHT, FHLC, and IYH in the table are broad ETFs that diversify across the healthcare sector. They are less volatile than BBP but offer less concentration in the biotech theme. XBI in the same table is similar to BBP in that it also concentrates on the biotech sector, but it differs by holding a broad range of companies without the commercial-stage filter. In addition, IBB and BBH, which invest more broadly in the biotech sector, and PBE, which also includes genomics-related companies, may be worth comparing. For short-term directional bets, LABU, a leveraged bullish product, and LABD, a product for betting on declines, can also be considered.
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 XLV | State Street Health Care Select Sector SPDR ETF | $184.91 | -2.5% | $50.9B | 0.08% | 1.38% | +26.9% |
 VHT | Vanguard Health Care ETF | $341.20 | -2.9% | $21.4B | 0.09% | 1.35% | +25.4% |
 XBI | State Street SPDR S&P Biotech ETF | $148.40 | -6.7% | $10.9B | 0.35% | 0.37% | +35.9% |
 IYH | iShares U.S. Healthcare ETF | $77.63 | -2.8% | $4.9B | 0.37% | 1.03% | +26.6% |
 IHI | iShares U.S. Medical Devices ETF | $59.03 | -2.0% | $4.2B | 0.37% | 0.44% | -2.6% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
 OABI | OmniAb Inc | - | $4.83 | -6.8% | $704.5M | - | - |
 IBRX | ImmunityBio Inc | 0.05% | $8.01 | -10.3% | $8.5B | - | - |
| MRNA | Moderna Inc | 0.02% | $241.46 | -6.5% | $96.4B | - | - |
 IOVA | Iovance Biotherapeutics Inc | 0.02% | $7.74 | -11.0% | $3.5B | - | - |
Investor Checkpoints for the Virtus LifeSci Biotech Products ETF
Here are the points to review before investing in BBP. Because it is a thematic ETF concentrated in commercial-stage biotech companies, you should check in advance the sector volatility, policy risk, and the impact of clinical and regulatory news on individual stocks.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 💵 Expense Ratio | Check the cumulative impact over a long holding period | Annual fee applies |
| 🧬 Sector Concentration | Whether the fund is concentrated in the single biotech sector | High concentration compared with broad healthcare funds |
| 📉 Volatility | Sensitivity to clinical and regulatory news on individual stocks | High volatility persists |
| 💊 Policy Risk | Changes in drug pricing and FDA regulatory policy | Ongoing monitoring required |
Stock-specific volatility from clinical and regulatory news and policy risk are the main drivers of short-term price swings. When the sector as a whole is weak, the fund can fall along with it despite the commercial-stage filter.
It is a thematic ETF suited to investors who want to focus within the biotech sector on commercial-stage companies with lower clinical failure risk. Investors must be able to tolerate the volatility that comes with sector concentration.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of July 2, 2026.
Today's 5 AI picks, all free